Now in its extensively revised third edition, this book offers a comprehensive review of the latest advancements in prostate cancer management, from screening to treatment, with a strong emphasis on a multidisciplinary approach. The editors present outstanding new and updated contributions from various expert authors.

The opening chapters cover fundamental aspects such as epidemiology, pathology, biology and genetics. The role of individual and mass screening is thoroughly evaluated, with significant attention given to diagnosis and clinical work-up using recent innovations like multiparametric MRI and choline PET-CT. The detailed examination of active surveillance is followed by discussions on various therapeutic options, including open and minimally invasive procedures, robot-assisted radical prostatectomy, different forms of radiation therapy, high-intensity focused ultrasound, cryotherapy, hormonal treatments, chemotherapy, targeted therapies, and immunotherapy. The book includes up-to-date results from practice-changing phase III randomized clinical trials and provides special insights into interpreting these results from both clinical and patient perspectives.

Management of Prostate Cancer will be a valuable resource for practitioners at all levels of expertise.

Doctor Michel Bolla was appointed Professor of Radiation Oncology at Grenoble-Alpes University (France) in 1986. He served as Head of the Radiation Oncology Department from 1997 to 2009 and was President of the Federation of Oncology at Grenoble University Hospital from 2000 to 2007. Additionally, he led the Arc Alpin Oncology Network from 2002 to 2009, facilitating collaboration between university and non-university hospitals to establish therapeutic guidelines. At the Isère Department level, he presided over the Onco-38 territorial network of Oncology from 2007 to 2012, optimizing patient care post-hospitalization. Doctor Bolla held key roles in the European Organization for Research and Treatment of Cancer (EORTC), serving as secretary (1990-1997), chairman (1997-2000), and board member (2000-2006). As President of the Société Française de Radiothérapie Oncologique (2006-2007), he contributed to defining radiotherapy quality criteria and managed the French Radiation Therapy Observatory. He was instrumental in promoting mass screening for breast, cervix, and colorectal cancers in Isère (1990) and collaborated with the EORTC Radiation Oncology Group to advance combined external irradiation and androgen deprivation for high-risk prostate cancer (NEJM 1997, Lancet 2002, NEJM 2009, Lancet Oncol 2010) and immediate post-operative irradiation (Lancet 2005, Lancet 2012). Doctor Bolla received the EMUC award for excellence in Radiation Oncology (2009) and the Klass Breuer Award from the European Society of Therapeutic Radiation Oncology (2012). He also served on the European Research Council's LS7 expert panel (2012-2018), Member of the Prostate Committee Guidelines of the European Association of Urology (2000-2022) and was President of the Isère Cancer Registry (2017-2023). He has published more than 720 peer-reviewed papers. Number of peer-reviewed publications =723; H-index=70; Number of citations= 47604.

Professor Hein Van Poppel, M.D., Ph.D., was the Chairman of the Department of Urology at University Hospital Gasthuisberg, Katholieke Universiteit Leuven, the largest urological training institute in Belgium. He graduated in General Surgery in 1980 and Urology in 1983, joining the academic unit at KU Leuven after two years of postgraduate training in London, Barcelona, Copenhagen, Mainz, and Rotterdam. In 1988, he earned a Ph.D. in Medical Sciences. He became a Fellow of the European Board of Urology in 1992 and a full Professor of Urology in 1993. Professor Van Poppel is a board member of the European Association of Urology (EAU) and the International Consultation on Urological Disease (ICUD). He has served as study coordinator and treasurer of the EORTC GU Group, Director of the European School of Urology, and Executive Board member of the EAU responsible for Education. Currently, he is Chairman of the Policy Office of the EAU and a member of the American Association of Genito Urinary Surgeons (AAGUS) and the Association of Academic European Urologists (AAEU). He has also been President of the Belgian Society of Urology (BVU), Chairman of the Scientific Committee of Europa Uomo, and a Faculty Member of the European Society of Medical Oncology (ESMO). He chairs the Scientific Advisory Committee of Cancer Patients Europe (CPE). His clinical focus has been on genitourinary cancer management and primary and salvage surgery for kidney, bladder, prostate, and testicular malignancies. Professor Van Poppel is a member of numerous scientific organizations in Europe and worldwide and a reviewer for prominent urological peer-reviewed journals. He has published over 250 papers as the first author on uro-oncological surgery and co-authored more than 500 other papers. Actually he is committed in the gradual introduction of  population based Prostate Cancer screening in Europe.